Press Releases

Date Title and Summary  
Toggle Summary Geron to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present a company overview at the following investor conferences: Stifel 2018 Healthcare Conference in New
Toggle Summary Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology Meeting (ASH) in December Conference call scheduled for 4:30 p.m. ET today MENLO PARK, Calif. , Nov.
Toggle Summary Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) --   Geron Corporation (Nasdaq: GERN) today announced that clinical data related to imetelstat, the Company’s
Toggle Summary Geron to Announce Third Quarter 2018 Financial Results on November 1, 2018
MENLO PARK, Calif. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2018 financial results after the market closes on Thursday, November 1, 2018 . The financial press release will be available on the Company’s website at
Toggle Summary Geron Announces Discontinuation of Imetelstat Collaboration by Janssen
Geron regains global rights to imetelstat program Highlights reported for IMerge and IMbark Geron plans to initiate the Phase 3 portion of IMerge Conference call scheduled for 8:00 a.m. ET today MENLO PARK, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced
Toggle Summary Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018
MENLO PARK, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to provide an update on the imetelstat collaboration with Janssen Biotech, Inc. (Janssen) on Thursday, September 27th at 8:00 a.m. ET .
Toggle Summary Geron Corporation Reports Second Quarter 2018 Financial Results and Recent Company Events
Conference Call Scheduled for July 31 at 4:30 p.m. ET MENLO PARK, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June 30, 2018 . Second Quarter and Year to Date 2018 Results For the second quarter of
Toggle Summary Geron to Announce Second Quarter 2018 Financial Results on July 31, 2018
MENLO PARK, Calif. , July 24, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that it will release its second quarter 2018 financial results after the market closes on Tuesday, July 31, 2018 . The financial press release will be available on the Company’s website at
Toggle Summary Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress
Updated Clinical Data from Original Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented MENLO PARK, Calif. , June 18, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the oral presentation of updated data from the ongoing original Part 1 of IMerge, the Phase 2/3
Toggle Summary Geron Announces Oral Presentation at European Hematology Association Congress
Updated Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented MENLO PARK, Calif. , May 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been